Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261068 | 0.92 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY12 | |
| SCHEMBL15261029 | 0.91 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY12 | |
| SCHEMBL2108638 | 0.90 | TYMP (0.46) | TYMPP2RY14P2RY2P2RY6P2RY12 | |
| SCHEMBL2108637 | 0.90 | TYMP (0.46) | TYMPP2RY14P2RY2P2RY6P2RY12 | |
| SCHEMBL15261113 | 0.90 | TYMP (0.47) | TYMPP2RY14P2RY2P2RY6P2RY12 | |
| SCHEMBL6831398 | 0.90 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL7553293 | 0.90 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL4451613 | 0.90 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6831397 | 0.90 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL15261272 | 0.89 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY6P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2647644-B1 | 2'-O-MODIFIED RNA | WAVE LIFE SCIENCES JAPAN INC (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-8822671-B2 | 2'-O-modified RNA | THE UNIVERSITY OF TOKYO (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2647644-A1 | 2'-O-MODIFIED RNA | Chiralgen, Ltd. (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253178-A1 | 2'-O-MODIFIED RNA | THE UNIVERSITY OF TOKYO (JP) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253178-A1 | 2'-O-MODIFIED RNA | METTL16, NSUN2, METTL3 | TYMP 1968/4885P2RY14 3871/4885P2RY2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.